Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision | |||
|
group_1_presentation_3_-_physiological_effects_of_caffeine [2020/03/25 15:27] ibrikr [References] |
group_1_presentation_3_-_physiological_effects_of_caffeine [2020/03/26 13:28] (current) guos13 |
||
|---|---|---|---|
| Line 1: | Line 1: | ||
| ====== Presentation Slides ====== | ====== Presentation Slides ====== | ||
| + | {{::lifesci_4m03_group1_caffeine.pptx|Caffeine Presentation}} | ||
| ====== Introduction ====== | ====== Introduction ====== | ||
| Line 64: | Line 64: | ||
| - | **Figure : Change in self-reported anxiety based on the Visual Analog Scale (VAS) after exposure to different doses of caffeine.** Data represents mean peak change from pre-caffeine baseline in participants post-caffeine exposure. Only the the highest dose of caffeine (450mg) significantly increased ratings of anxiety (p-value<0.01). (Childs et al., 2008). | + | **Figure 3: Change in self-reported anxiety based on the Visual Analog Scale (VAS) after exposure to different doses of caffeine.** Data represents mean peak change from pre-caffeine baseline in participants post-caffeine exposure. Only the the highest dose of caffeine (450mg) significantly increased ratings of anxiety (p-value<0.01). (Childs et al., 2008). |
| </WRAP> | </WRAP> | ||
| Line 80: | Line 80: | ||
| - | **Figure : Change in self-reported anxiety based on the Profile of Mood States (POMS) after exposure to placebo and 150mg of caffeine.** Between the three genotypic groups, only the 1976T/T groups reported significant increase in anxiety. (Alsene et al., 2003). | + | **Figure 4: Change in self-reported anxiety based on the Profile of Mood States (POMS) after exposure to placebo and 150mg of caffeine.** Between the three genotypic groups, only the 1976T/T groups reported significant increase in anxiety. (Alsene et al., 2003). |
| </WRAP> | </WRAP> | ||
| Line 89: | Line 89: | ||
| - | **Figure : Change in self-reported anxiety based on the Visual Analog Scale (VAS) after exposure to placebo and 150mg of caffeine.** Between the three genotypic groups, only the 1976T/T groups reported significant increase in anxiety. (Alsene et al., 2003). | + | **Figure 5: Change in self-reported anxiety based on the Visual Analog Scale (VAS) after exposure to placebo and 150mg of caffeine.** Between the three genotypic groups, only the 1976T/T groups reported significant increase in anxiety. (Alsene et al., 2003). |
| </WRAP> | </WRAP> | ||
| Line 131: | Line 131: | ||
| {{ :what-to-expect-from-caffeine-withdrawal-21844-v1-5c521bb246e0fb000180a7ec.png?nolink&500 |}} | {{ :what-to-expect-from-caffeine-withdrawal-21844-v1-5c521bb246e0fb000180a7ec.png?nolink&500 |}} | ||
| - | **Figure : Common symptoms resulting from cessation of caffeine.** Withdrawal from caffeine causes mild to clinically significant distress and impairment of daily functioning. Caffeine withdrawal symptoms begin around 12-24 hours after cessation of caffeine intake and reach maximum intensity 20-48 hours after abstinence (Schuh and Griffiths, 1997). Common symptoms include headaches, fatigue, decreased alertness, nausea and a negative mood. | + | **Figure 6: Common symptoms resulting from cessation of caffeine.** Withdrawal from caffeine causes mild to clinically significant distress and impairment of daily functioning. Caffeine withdrawal symptoms begin around 12-24 hours after cessation of caffeine intake and reach maximum intensity 20-48 hours after abstinence (Schuh and Griffiths, 1997). Common symptoms include headaches, fatigue, decreased alertness, nausea and a negative mood. |
| </WRAP> | </WRAP> | ||
